ArticleBMJ oncology2025

Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011-2023: a cross-sectional analysis.

Martin Kurian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.